Clinical Trials

866 enrolled 25 charts 1 FDA

Breast Neoplasms

NCT03523585 2026-02-27

DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]

608 enrolled 17 charts

Phase 1 Active not recruiting

Breast Neoplasms

NCT04288089 2026-02-27

A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer

31 enrolled 12 charts

Breast Neoplasms

NCT01597388 2026-02-24

AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast Cancer

Phase 1 Completed

99 enrolled 61 charts

Advanced Metastatic Breast Cancer

NCT04059484 2026-02-24

AMEERA-3

367 enrolled 30 charts

Breast Cancer Metastatic

NCT04024462 2026-02-20

A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer

200 enrolled 16 charts

HER2-positive Early Breast Cancer

NCT02032823 2026-02-17

OlympiA

1,836 enrolled 20 charts 1 FDA

Breast Neoplasms

NCT02000622 2026-02-13

OlympiAD

302 enrolled 26 charts 1 FDA

Breast Neoplasms, Neoplasm Metastasis

NCT02499146 2026-02-11

Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast Cancer

Phase 1 Completed

26 enrolled 40 charts

Advanced Breast Cancer

NCT04739761 2026-02-11

DESTINY-B12

506 enrolled 27 charts

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT05415215 2026-02-10

ProHer

346 enrolled 20 charts

Phase 2 Active not recruiting

Breast Neoplasms, Patient Preference, Inflammatory Breast Neoplasms

NCT02747004 2026-02-06

Next MONARCH 1

234 enrolled 20 charts

Breast Neoplasms

NCT02763566 2026-02-05

MONARCH plus

463 enrolled 20 charts

Breast Neoplasms

NCT05104866 2026-02-04

A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)

732 enrolled 22 charts 1 FDA

Breast Neoplasms, Neoplasm Metastasis

NCT02246621 2026-02-03

MONARCH 3

493 enrolled 23 charts 1 FDA

Phase 1/2 Active not recruiting

Breast Neoplasms

NCT03742102 2026-02-02

BEGONIA

243 enrolled 13 charts

Phase 1/2 Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02734004 2026-01-29

MEDIOLA

264 enrolled 32 charts

BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Small Cell Lung Carcinoma

NCT05070247 2026-01-22

A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors

Phase 1/2 Terminated

61 enrolled 29 charts

BreastGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Kidney Neoplasms, Liver Neoplasms, Mesothelioma, Nasopharyngeal Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms

NCT04576455 2026-01-16

A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)

Phase 2 Active not recruiting

303 enrolled 23 charts

Breast Neoplasms

NCT05169567 2026-01-16

postMONARCH

368 enrolled 14 charts

Breast Neoplasms, Neoplasm Metastasis

NCT03056755 2026-01-13

BYLieve

Phase 2 Completed

383 enrolled 16 charts

Phase 2 Active not recruiting

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies

NCT04721977 2026-01-09

MK-7119-001

66 enrolled 7 charts

Phase 1/2 Active not recruiting

Breast Neoplasms

NCT03899792 2026-01-06

LIBRETTO-121

36 enrolled 13 charts 2 FDA

BreastCNSEndocrineGastrointestinalHead & NeckSarcomaThoracic

Thyroid Cancer, Papillary, Breast Neoplasms, Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Endocrine System Diseases, Endocrine Gland Neoplasms, Head and Neck Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Sarcoma, Thoracic Neoplasms, Thyroid Diseases, Thyroid Neoplasms, Central Nervous System Neoplasms, Myofibromatosis, Carcinoma, Medullary

NCT05524454 2026-01-06

CONFIGURE

Phase NA Completed

41 enrolled 6 charts

BreastGynecologicHead & NeckThoracic

Breast Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Pelvic Neoplasms

NCT04148911 2025-12-26

EL1SSAR

184 enrolled 15 charts

BreastGastrointestinalGynecologicHead & NeckThoracic

Triple Negative Breast Neoplasms

NCT05001347 2025-12-16

A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors

Phase 2 Completed

25 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT03310957 2025-12-12

Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer

Phase 1/2 Completed

185 enrolled 23 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03975647 2025-12-10

A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer

466 enrolled 17 charts

HER2-positive Breast Cancer

NCT04671615 2025-12-10

A Study to Understand the Treatment Patterns and Patients and Their Clinical Outcomes Who Are Taking Palbociclib in a Real Life Setting in Israel.

Completed

559 enrolled 26 charts

Breast Neoplasms

NCT04735367 2025-12-09

Study to Evaluate Overall Survival in Japanese Patients With HR+/HER2- Advanced Breast Cancer Treated With Palbociclib Plus Letrozole

Completed

42 enrolled 7 charts

Breast Neoplasms

NCT01358877 2025-11-28

APHINITY

4,804 enrolled 45 charts 1 FDA

Breast Neoplasms

NCT05757427 2025-11-26

Pilot Clinical Evaluation of a Microwave Imaging System for Breast Cancer Detection

Phase NA Completed

73 enrolled 7 charts

BreastGastrointestinalGenitourinaryThoracic

Breast Neoplasms

NCT01147965 2025-11-25

QUILT-3.038: Active Immunotherapy CEA Vaccine in Patients With Malignancies Expressing CEA

Phase 1/2 Completed

43 enrolled 15 charts

Breast Neoplasms, Colonic Neoplasms, Lung Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

NCT03284957 2025-11-24

AMEERA-1

Phase 1/2 Terminated

136 enrolled 60 charts

Breast Neoplasms

NCT05954143 2025-11-20

Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer

11 enrolled 13 charts

Breast Neoplasms

NCT06086340 2025-11-18

Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.

Completed

779 enrolled 9 charts

Breast Neoplasms, Neoplasm Metastasis

NCT03519178 2025-11-14

A Study of PF-06873600 in People With Cancer

Phase 1/2 Terminated

155 enrolled 44 charts

BreastGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

NCT04024436 2025-11-13

A Study of TAS-120 in Patients With Metastatic Breast Cancer

64 enrolled 21 charts

Breast Neoplasms

NCT03371017 2025-11-12

IMpassion132

595 enrolled 37 charts

Triple Negative Breast Neoplasms

NCT04647487 2025-11-12

EMBER-2

Phase 1 Completed

87 enrolled 13 charts

Breast Neoplasms

NCT03280563 2025-11-10

MORPHEUS HR+BC

Phase 1/2 Completed

144 enrolled 25 charts

Breast Neoplasms

NCT04504916 2025-11-10

MK-2140-002

102 enrolled 36 charts

BreastGastrointestinal

Pancreatic Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT04958785 2025-11-04

ELEVATE TNBC

92 enrolled 27 charts

Triple Negative Breast Neoplasms

NCT05169437 2025-10-29

PAVO